Brief: Precigen Regains Exclusive Rights To Proven Car-T Targets, Cd19 and BCMA, To Enable Unencumbered Development And Commercialization Of Ultracar-T®

Precigen

03/04/2023 21:31

April 3 (Reuters) - Precigen Inc  PGEN.O :
    * PRECIGEN REGAINS EXCLUSIVE RIGHTS TO PROVEN CAR-T TARGETS,
CD19
AND BCMA, TO ENABLE UNENCUMBERED DEVELOPMENT AND
COMMERCIALIZATION OF ULTRACAR-T®
    * PRECIGEN INC - PRECIGEN AMENDS EXCLUSIVE LICENSE AGREEMENT
WITH
ALAUNOS TO BOLSTER PORTFOLIO AND BROADEN STRATEGIC OPPORTUNITIES
    * PRECIGEN INC - AGREEMENT ELIMINATES ALL FUTURE ROYALTIES
TO
ALAUNOS
    * PRECIGEN INC - COMPANY ALSO REGAINS EXCLUSIVE RIGHTS TO
IL-12
GENE THERAPY, INCLUDING APPLICATION THROUGH ADENOVERSE™ PLATFORM

Source text for Eikon:  ID:nPn3QBwyRa 
Further company coverage:  PGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))